PetMed Express (PETS)
(Delayed Data from NSDQ)
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
Zacks News
Amazon (AMZN) Rules E-Commerce: 3 Contenders to Watch Out
by Zacks Equity Research
Companies like EVINE Live Inc. (EVLV), PetMed Express, Inc. (PETS) and Wal-Mart Stores Inc. (WMT) are likely to gain from the growing e-commerce market.
The Zacks Analyst Blog Highlights: CVS Health, Aetna, PetMed Express, Align Technology and Myriad Genetics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CVS Health, Aetna, PetMed Express, Align Technology and Myriad Genetics
First Data (FDC) Acquires BluePay, Boosts Service Offerings
by Zacks Equity Research
First Data Corporation (FDC) acquires BluePay Holdings to expand its offerings in the high-growth integrated payments space.
Ecolab Focuses on Pest Elimination, Acquires 3 Companies
by Zacks Equity Research
Ecolab (ECL) continues to focus on investment in key growth businesses and bolt-on acquisitions to gain market traction and boost profits and inorganic growth.
Quest Diagnostics Banks on Buyouts to Expand in Diagnostic
by Zacks Equity Research
Quest Diagnostics (DGX) actively pursues merger and acquisitions to solidify hold in the high-potential diagnostic information services market. Notably, Cleveland HeartLab buyout marks as the latest deal.
Patterson Companies-SprintRay Deal to Boost Dental Unit
by Zacks Equity Research
Patterson Companies (PDCO) focuses on acquisitions to boost dental segment.
CVS Health's Aetna Buyout to Change Healthcare Landscape
by Zacks Equity Research
Once the Aetna deal is through, CVS Health (CVS) expects to draw $750 million from near-term synergies with low to mid-single digit accretion in the second year.
Cooper Companies' (COO) CooperVision Buys Paragon for $80M
by Zacks Equity Research
The Cooper Companies (COO) focuses on strategic acquisitions to drive inorganic growth.
Boston Scientific (BSX) Shares Drop on LOTUS Relaunch Delay
by Zacks Equity Research
Boston Scientific (BSX) announces a delay in deadline for the commercial return of the LOTUS Edge Aortic Valve System in Europe. Following this news, share price declines.
BioTelemetry's (BEAT) Telcare Unit Collaborates With Onduo
by Zacks Equity Research
BioTelemetry (BEAT) progresses with deals to strengthen hold in the high-potential diabetes care market.
ResMed (RMD) Rides on Innovation Amid Reimbursement Woes
by Zacks Equity Research
ResMed (RMD) achieves strong global revenue growth for the past few quarters on the back of sales of sleep devices, respiratory care devices, mask systems and software solutions.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Chemed (CHE) continues to ride high on strength in Roto-Rooter business.
Bio-Rad (BIO) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Bio-Rad (BIO) consistently invests in R&D for product innovation.
BioTelemetry Ties Up With Apple, Grows in Cardiac Monitoring
by Zacks Equity Research
BioTelemetry (BEAT) is consistently trying to improve its position in the cardiac monitoring and diagnostic services space.
Flexion's (FLXN) Zilretta Therapy to Fast Capture OA Market
by Zacks Equity Research
Flexion's (FLXN) commercial launch of Zilretta seems well-timed keeping in view how rapidly the osteoarthritis market is growing worldwide.
Veeva Systems (VEEV) Grows in Digital Asset Management Space
by Zacks Equity Research
Veeva Systems' (VEEV) constant endeavors seem to boost the Veeva Vault portfolio.
Amazon (AMZN) Witnesses Biggest Cyber Monday Bonanza Ever
by Zacks Equity Research
Cyber Monday becomes single biggest shopping day ever for Amazon.com Inc. (AMZN).
Here's Why You Should Invest in Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter has witnessed favorable tidings on the regulatory front. The company enjoys strong presence in foreign markets.
Varian's Partners Penn Medicine, Proton Therapy in Focus
by Zacks Equity Research
Varian Medical's (VAR) solid prospects on the proton therapy space holds promise at the moment.
Genomic Health-Cleveland Diagnostics Deal to Boost Test Suite
by Zacks Equity Research
Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.
GNC Holdings Grapples With Margin Weakness, Stiff Competition
by Zacks Equity Research
Weak margins, declining year-over-year revenues and rising operating costs continue to pose challenges to GNC Holdings (GNC).
Stryker Gains Ground on MAKO Robotic Unit Amid Forex Woes
by Zacks Equity Research
Solid performance by the MAKO robotic platform has been boosting Stryker's (SYK) revenues for long.
LabCorp's Covance Business Bounces Back on Chiltern Buyout
by Zacks Equity Research
Despite a dull show for several quarters, LabCorp's (LH) Covance Drug Development reported strong growth in the third quarter, courtesy of Chiltern acquisition. However, volume woes remain.
Align Technology (ALGN) Grows on InvisAlign System Strength
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strength in the InvisAlign space.
Edwards Lifesciences' Pipeline Strong Amid Rising Expenses
by Zacks Equity Research
Edwards Lifesciences' (EW) aim at building its pipeline to fortify foothold across all operating businesses augurs well for the company. However, higher operating expenses are a concern.